NEW YORK, Sept. 23 (GenomeWeb News) - ParAllele BioScience said that it has raised $22.5 million in a round of Series B financing.

The round was led by a new investor, Mohr, Davidow Ventures, and included such existing investors as Abingworth Management, Index Ventures, and Versant Ventures.

Proceeds of the financing, said ParAllele, will be used to support the ongoing development and roll out of the company's SNP products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.